224 related articles for article (PubMed ID: 19815062)
41. Haste Makes Waste: The Interplay Between Dissolution and Precipitation of Supersaturating Formulations.
Sun DD; Lee PI
AAPS J; 2015 Nov; 17(6):1317-26. PubMed ID: 26338234
[TBL] [Abstract][Full Text] [Related]
42. Ex vivo permeability experiments in excised rat intestinal tissue and in vitro solubility measurements in aspirated human intestinal fluids support age-dependent oral drug absorption.
Annaert P; Brouwers J; Bijnens A; Lammert F; Tack J; Augustijns P
Eur J Pharm Sci; 2010 Jan; 39(1-3):15-22. PubMed ID: 19837159
[TBL] [Abstract][Full Text] [Related]
43. Parallel screening approach to identify solubility-enhancing formulations for improved bioavailability of a poorly water-soluble compound using milligram quantities of material.
Dai WG; Dong LC; Li S; Pollock-Dove C; Chen J; Mansky P; Eichenbaum G
Int J Pharm; 2007 May; 336(1):1-11. PubMed ID: 17178444
[TBL] [Abstract][Full Text] [Related]
44. Analysis of solid-state transformations of pharmaceutical compounds using vibrational spectroscopy.
Heinz A; Strachan CJ; Gordon KC; Rades T
J Pharm Pharmacol; 2009 Aug; 61(8):971-88. PubMed ID: 19703341
[TBL] [Abstract][Full Text] [Related]
45. Aqueous solubility: simple predictive methods (in silico, in vitro and bio-relevant approaches).
Elder D; Holm R
Int J Pharm; 2013 Aug; 453(1):3-11. PubMed ID: 23124107
[TBL] [Abstract][Full Text] [Related]
46. Risk assessment and physicochemical characterization of a metastable dihydrate API phase for intravenous formulation development.
Mortko CJ; Sheth AR; Variankaval N; Li L; Farrer BT
J Pharm Sci; 2010 Dec; 99(12):4973-81. PubMed ID: 20821397
[TBL] [Abstract][Full Text] [Related]
47. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs.
Dahan A; Hoffman A
J Control Release; 2008 Jul; 129(1):1-10. PubMed ID: 18499294
[TBL] [Abstract][Full Text] [Related]
48. Deliquescence of pharmaceutical systems.
Mauer LJ; Taylor LS
Pharm Dev Technol; 2010 Dec; 15(6):582-94. PubMed ID: 19895256
[TBL] [Abstract][Full Text] [Related]
49. The utility of cyclodextrins for enhancing oral bioavailability.
Carrier RL; Miller LA; Ahmed I
J Control Release; 2007 Nov; 123(2):78-99. PubMed ID: 17888540
[TBL] [Abstract][Full Text] [Related]
50. The effects of food on the dissolution of poorly soluble drugs in human and in model small intestinal fluids.
Persson EM; Gustafsson AS; Carlsson AS; Nilsson RG; Knutson L; Forsell P; Hanisch G; Lennernäs H; Abrahamsson B
Pharm Res; 2005 Dec; 22(12):2141-51. PubMed ID: 16247711
[TBL] [Abstract][Full Text] [Related]
51. A simulation of oral absorption using classical nucleation theory.
Sugano K
Int J Pharm; 2009 Aug; 378(1-2):142-5. PubMed ID: 19501145
[TBL] [Abstract][Full Text] [Related]
52. A comparative in vitro assessment of the drug release performance of pH-responsive polymers for ileo-colonic delivery.
Ibekwe VC; Fadda HM; Parsons GE; Basit AW
Int J Pharm; 2006 Feb; 308(1-2):52-60. PubMed ID: 16356670
[TBL] [Abstract][Full Text] [Related]
53. Simulating fasted human intestinal fluids: understanding the roles of lecithin and bile acids.
Söderlind E; Karlsson E; Carlsson A; Kong R; Lenz A; Lindborg S; Sheng JJ
Mol Pharm; 2010 Oct; 7(5):1498-507. PubMed ID: 20698569
[TBL] [Abstract][Full Text] [Related]
54. Solid form screening--a review.
Aaltonen J; Allesø M; Mirza S; Koradia V; Gordon KC; Rantanen J
Eur J Pharm Biopharm; 2009 Jan; 71(1):23-37. PubMed ID: 18715549
[TBL] [Abstract][Full Text] [Related]
55. In Vitro Sensitivity Analysis of the Gastrointestinal Dissolution Profile of Weakly Basic Drugs in the Stomach-to-Intestine Fluid Changing System: Explanation for Variable Plasma Exposure after Oral Administration.
Takagi T; Masada T; Minami K; Kataoka M; Izutsu KI; Matsui K; Yamashita S
Mol Pharm; 2021 Apr; 18(4):1711-1719. PubMed ID: 33629861
[TBL] [Abstract][Full Text] [Related]
56. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling.
Shono Y; Jantratid E; Janssen N; Kesisoglou F; Mao Y; Vertzoni M; Reppas C; Dressman JB
Eur J Pharm Biopharm; 2009 Sep; 73(1):107-14. PubMed ID: 19465123
[TBL] [Abstract][Full Text] [Related]
57. An in vitro-in silico-in vivo approach to predicting the oral pharmacokinetic profile of salts of weak acids: case example dantrolene.
Kambayashi A; Dressman JB
Eur J Pharm Biopharm; 2013 May; 84(1):200-7. PubMed ID: 23262163
[TBL] [Abstract][Full Text] [Related]
58. Development of an in vitro/in vivo correlation for lipid formulations of EMD 50733, a poorly soluble, lipophilic drug substance.
Schamp K; Schreder SA; Dressman J
Eur J Pharm Biopharm; 2006 Apr; 62(3):227-34. PubMed ID: 16246538
[TBL] [Abstract][Full Text] [Related]
59. Comparison of bovine in vivo bioavailability of two sulfamethazine oral boluses exhibiting different in vitro dissolution profiles.
Martinez MN; Kawalek JC; Howard KD; Ward JL; Marroum P; Marnane W; Bensley D; Pelsor FR; Hoag S; Tatavarti AS; Xie L; Fahmy R
J Vet Pharmacol Ther; 2006 Dec; 29(6):459-67. PubMed ID: 17083449
[TBL] [Abstract][Full Text] [Related]
60. Dissolution media simulating the intralumenal composition of the small intestine: physiological issues and practical aspects.
Vertzoni M; Fotaki N; Kostewicz E; Stippler E; Leuner C; Nicolaides E; Dressman J; Reppas C
J Pharm Pharmacol; 2004 Apr; 56(4):453-62. PubMed ID: 15099440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
